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Background: Preeclampsia is a hypertensive, multi-system pregnancy disorder whose pathophysiology remains
unclear. Elevations in circulating soluble endoglin (sENG) and placental/blood ENG mRNA expression antedate the
clinical onset of preeclampsia. This study investigated if endoglin (ENG) pathway genetic variation was also
associated with the development of preeclampsia.
Methods: We used a case–control candidate gene association design. Data from 355 white (181 preeclampsia
cases/174 controls) and 60 black (30 preeclampsia cases/30 controls) women matched on ancestry, age, and parity
were analyzed. Tagging single nucleotide polymorphisms (tSNPs) and potentially functional SNPs in ENG, TGFβ1,
TGFβR1, ALK1, and TGFβR2 were genotyped with iPLEXW and TaqManW. Chi-square or Fisher’s exact tests were used
to conduct allele/genotype/haplotype tests in white/black subgroups separately. Odds ratios were computed with
binary logistic regression for tSNPs with significant genotype tests.
Results: Of the 49 SNPs evaluated, variation in two ENG tSNPs (rs11792480, rs10121110) and one TGFβR2 tSNP
(rs6550005) was associated with preeclampsia in white women (P <0.05, each). In black women, variation in two
TGFβ1 tSNPs (rs4803455, rs4803457), one TGFβR1 tSNP (rs10739778), and three TGFβR2 tSNPs (rs6550005, rs1346907,
rs877572) was associated with preeclampsia (P <0.05, each). Further evaluation of ENG tSNP rs10121110 revealed
that white women inheriting the AA genotype were 2.29 times more likely to develop preeclampsia compared to
the GG genotype (P = 0.008, [99% CI: 1.02 to 5.13]). For black women, similar evaluation of TGFβ1 tSNP rs4803457
revealed women inheriting the CT genotype were 7.44 times more likely to develop preeclampsia than those with
the CC genotype (P = 0.005, [99% CI: 1.19 to 46.41]).
Conclusions: ENG pathway genetic variation is associated with preeclampsia. Different ENG pathway genes may be
involved in preeclampsia development among white and black women. Additional studies are needed to validate
these findings and to determine if genetic variation in ENG pathway genes impacts ENG and sENG levels in
preeclampsia.
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Preeclampsia is a multi-system disorder of pregnancy
that complicates 3-5% of pregnancies [1] and is diag-
nosed by new onset hypertension and proteinuria after
20 weeks’ gestation [2,3]. The heterogeneous nature of
preeclampsia suggests that multiple mechanisms lead to
its development. Research has identified endoglin (ENG)
as a mechanism that may contribute to preeclampsia in
some women.
ENG is a trans-membrane glycoprotein that serves as
a co-receptor of the transforming growth factor beta
(TGFβ) signaling system [4]. It is expressed on vascular
endothelial cells [5], synctyiotrophoblasts, and invasive
cytotrophoblasts of cell columns [6]. ENG is involved in
maintenance of vascular tone through regulation of ni-
tric oxide dependent vasodilatation [7,8], and likely con-
tributes to regulation of placental implantation and
spiral artery remodeling during pregnancy [9,10]. Inhib-
ition of ENG translation in first trimester human villous
explants [9] or a human extravillous tropholast cell line
[10] improves the invasive capacity of extravillous tro-
phoblasts. Invasion of extravillous trophoblasts is pro-
posed to be vital to uterine spiral artery remodeling,
which increases placental perfusion during pregnancy
[9,10].
Because systemic endothelial dysfunction and shallow
placental implantation/spiral artery remodeling repre-
sent hallmark abnormalities of preeclampsia [11], ENG’s
potential role has been investigated. In multiple studies,
ENG gene expression (mRNA) is increased in placenta
and/or cellular/non-cellular components of blood
throughout pregnancy in women who develop pre-
eclampsia [12-18]. Soluble endoglin (sENG), which is re-
leased into circulation after cleavage of trans-membrane
ENG by matrix metalloproteinase-14 (MMP-14) [19], is
also elevated in preeclampsia [20]. Our study proposed
to test the role of ENG in preeclampsia by assessing if
ENG pathway genetic variations are associated with
preeclampsia.
Methods
Study population
Subjects were from the Prenatal Exposures and Pre-
eclampsia Prevention (PEPP) study. Conducted at
Magee-Womens Hospital of UPMC (Pittsburgh, PA),
PEPP examines factors predisposing women to pre-
eclampsia via two recruitment approaches. Women ages
14-44 were enrolled during early pregnancy (≤ 20 weeks’
gestation) and followed through delivery/postpartum
while other women were enrolled at the labor/delivery
unit due to suspected preeclampsia. Women with a history
of chronic renal disease, hypertension, diabetes, or other
disorders increasing risk of preeclampsia were excluded.
Genomic DNA was extracted from peripherally collectedvenous blood samples. The University of Pittsburgh and
Magee-Womens Hospital Institutional Review Board ap-
proved all aspects of PEPP and this study. We excluded
subjects not consenting to genetic evaluation and subjects
without a stored genetic sample.
Phenotype classifications
Preeclampsia was defined as gestational hypertension
and blood pressure increase, proteinuria, and hyperuri-
cemia. These criteria were reviewed by a panel of clini-
cians/researchers to determine preeclampsia diagnosis.
The average of the last five blood pressures taken in the
hospital prior to therapeutic intervention was compared
to average blood pressure prior to 20 weeks’ gestation to
establish the presence/absence of a relevant increase of
blood pressure. Gestational hypertension was defined as
a blood pressure ≥ 140 mmHg systolic and/or 90 mmHg
diastolic AND an increase of blood pressure > 30 mmHg
systolic and/or 15 mmHg diastolic after 20 weeks’ gesta-
tion. Proteinuria was defined as ≥ 300 mg/24 hours, ≥ 0.3
protein/creatinine ratio, ≥ 2+ on a random urine speci-
men, or ≥ 1+ on a catheterized urine specimen. Hyper-
uricemia was a serum uric acid concentration > 1
standard deviation from normal for gestational age [21].
Severe preeclampsia was preeclampsia plus ≥ 1 of the
following: (a) systolic blood pressure ≥ 160 mmHg, (b)
diastolic blood pressure ≥ 110 mmHg, (c) proteinuria ≥
5 grams/24 hours, (d) elevated liver enzymes, or (e)
platelet count ≤ 100,000. Hemolysis, elevated liver en-
zymes, and low platelets in subjects with preeclampsia
indicated HELLP syndrome. The case group included
PEPP subjects diagnosed with preeclampsia, severe pre-
eclampsia, or HELLP syndrome.
Women with normal medical histories (e.g., without
chronic renal disease, hypertension, diabetes) that did
not meet criteria for preeclampsia, severe preeclampsia,
or HELLP syndrome were designated as healthy con-
trols. Controls delivering prematurely (< 37 weeks’ gesta-
tion at delivery) were excluded from our analysis. A total
of 215 controls were 1:1 frequency matched to 215 cases
on ancestry (self-reported race), age, and parity. Data on
355 white (181 cases/174 controls) and 60 black (30
cases/30 controls) women were analyzed. In the white
case group, 161 (89.0%) subjects were diagnosed with
PE, 19 (10.5%) subjects were diagnosed with severe PE,
and 1 (0.6%) subject was diagnosed with HELLP syn-
drome. In the black case group, 27 (90%) subjects were
diagnosed with PE, 2 (6.7%) subjects were diagnosed
with severe PE, and 1 (3.3%) subject was diagnosed with
HELLP syndrome.
Polymorphism selection
Genetic variability of the candidate genes and their regu-
latory regions was evaluated with tagging single
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HapMap (HapMap Data Phase III/Rel#2, Feb09, on
NCBI B36 assembly, dbSNP b126). Selection criteria of
tSNPs included: minor allele frequency ≥20%, R2 cutoff =
0.8, and CEU ancestry. Forty-seven tSNPs were identified.
These tSNPs and two potentially functional SNPs identi-
fied in the literature were studied. The UCSC Genome
Browser [22] and Database of Single Nucleotide Polymor-
phisms were used to identify SNP nucleotide positions/
genomic locations.Genotyping methods
The 49 SNPs were genotyped with the iPLEXW Gold-
SNP Genotyping assay (SequenomW Inc, San Diego, CA)
(Table 1). Five SNPs (rs1800468, rs10739778, rs6809777,
rs3087465, rs8179181) not meeting data quality criteria
(call rate < 86% or multi-allelic >2 alleles) with iPLEXW
were genotyped by TaqManW allelic discrimination (Ap-
plied BiosystemsW).Genotype data reliability, haplotype assignment, and
linkage disequilibrium estimation
Genotype reliability checks included comparing expected
to observed homozygosity, comparing study and dbSNP
allele frequencies, evaluating genotype call rates, includ-
ing blind duplicates, double calling genotypes, and
checking Hardy-Weinberg Equilibrium (HWE). HWE
calculations were conducted with PLINK v1.07 [23] or
an online HWE calculator. ENG haplotypes and pair-
wise linkage disequilibrium (R2) were estimated in non-
related white and black subgroups separately using
PLINK. Further black subgroup haplotype analysis was
not conducted due to small sample size and haplotype
frequencies.Table 1 tSNPS examined in iPLEXW assays
Assay 1
Gene rs numbers Gene rs
Endoglin (ENG) rs10987746, rs10819309,
rs10760505, rs11792480,
rs10121110
TGFβR2 rs2
rs3
rs1
rs6
rs6Transforming growth
factor beta 1 (TGFβ1)
rs4803455, rs1800469, rs4803457,
rs8179181, rs1800468, rs11466314
Transforming growth
factor beta receptor 1
(TGFβR1)
rs6478974, rs420549, rs10739778
Activin receptor like kinase
1 (ALK1)
rs3759178, rs11169953, rs706819
Transforming growth
factor beta receptor 2
(TGFβR2)
rs749794, rs3087465
Note. The online Human GenoTyping Tools and MassARRAYW Assay Designer v4.0 s
assays. To optimize the multiplex reactions, tSNPs were grouped into Assay 1 or AsStatistical analysis
A power analysis was conducted with Quanto version
1.2.4 (Additional file 1).
White and black subgroups were evaluated separately.
Demographic characteristics were compared between
cases and controls. Continuous variables were assessed
with independent samples t-tests, independent samples
t-tests with unequal variances, or Mann–Whitney U
tests. Categorical variables were assessed with the
Mann–Whitney U test or the χ2 test of independence.
Missing pre-pregnancy body mass index values were es-
timated with multiple imputation.
Deviations from HWE were assessed with a χ2
goodness-of-fit test or an exact test. For SNPs violating
HWE (P < 0.05), HWE consistency was further assessed
in cases and controls separately. We concluded that any
SNP violating HWE in the entire group was due to en-
richment for preeclampsia in cases and non-
preeclampsia in controls and not due to genotyping
error.
Associations between SNP alleles and preeclampsia
status (allele test) were assessed with a χ2 test of inde-
pendence. Associations between SNP genotypes and pre-
eclampsia status (genotype test) were tested with a χ2
test of independence or Fisher’s exact test. SNPs with
homozygote variant frequencies of < 10% in cases, con-
trols, or both were dichotomized (homozygote wildtype;
homozygote variant + heterozygote) before genotype
testing. Given the exploratory nature of this study, we
used a less stringent significance criterion of P < 0.05 to
initially evaluate our genotype test results and identify
potentially interesting hits. SNPs with significant find-
ings (P < 0.05) on genotype tests were further analyzed
with binary logistic regression (odds ratio and 99% CI).
A 99% CI was selected for these analyses as a way to re-
duce the potential for Type 1 error due to multipleAssay 2
numbers
043136, rs13075948, rs1346907, rs3773652, rs4955212, rs1155708,
773640, rs1036097, rs2082224, rs876688, rs744751, rs1078985,
7025785, rs877572, rs5020833, rs6809777, rs6802220, rs9843942,
550005, rs3773644, rs3773645, rs13083813, rs12487185, rs13086588,
792117, rs3773663, rs4522809, rs11129420, rs995435, rs11924422
oftware (http://www.mysequenom.com) were used to design the iPLEXW
say 2.
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(SPSS Inc., Chicago, IL.).
The most probable ENG haplotypes estimated for each
white subject were selected for analysis. Haplotype fre-
quencies with < 10% in cases, controls, or both were col-
lapsed into one category (Additional file 1: Table S1). A
χ2 test of independence was used to determine if haplo-
type frequency distributions differed in cases and con-
trols. Separate pair-wise comparisons of haplotype
frequency distributions were also analyzed. The associ-
ation between diplotypes, which were generated from
ENG haplotypes, and preeclampsia status was assessed
with a χ2 test of independence.
Results
Allele/genotype findings support association between
ENG pathway genetic variation and preeclampsia
Tables 2 and 3 provide demographic/clinical characteris-
tics for white and black subgroups and reveal the success
of matching (ancestry, age, and parity) and the expected
differences between women with preeclampsia and con-
trols (blood pressure, gestational age at delivery, and
BMI). Additional file 1: Tables S2-S5 provide descriptive
information and allele/genotype test results.
We examined if the proportion of alleles for each of
the 49 SNPs (allele 1 or allele 2) differed in women with
preeclampsia compared to controls. Using P < 0.05 to in-
dicate statistical significance, allelic frequency distribu-
tions for two tSNPs in ENG (rs11792480: G/A alleles;
rs10121110: A/G alleles) and one tSNP in TGFβR2
(rs6550005: G/A alleles) were significantly different inTable 2 White subgroup demographic and clinical characteris
Variable Cases (n = 181
Maternal age, years (M (SD)) 28.3 (5.8)
Gravida (Mdn (min-max)) 1 (1-6)
Nulliparous (n, %) 146 (80.7%)
Gestational age at delivery, wks (M (SD)) 36.1 (3.2)
Birthweight, grams (M (SD))e 2497.5 (841.2)
Avg. SBP < 20 weeks’, mm Hg (M (SD))f 116.6 (9.6)
Avg. DBP < 20 weeks’, mm Hg (M (SD)) f 71.7 (7.2)
Avg. SBP in labor, mm Hg (M (SD))g 154.8 (13.9)
Avg. DBP in labor, mm Hg (M (SD))h 92.6 (8.0)
Pre-pregnancy BMI (Mdn (min-max))i 25.8 (17-46)
Abbreviations: (M (SD)), mean (standard deviation); (Mdn (min-max)), median (minim
millimeters of mercury; Avg. DBP, average diastolic blood pressure; BMI, body mass
a Independent samples t-test.
b Mann–Whitney U test.
c χ2 test of independence.
d Independent samples t-test with unequal variance.
e Outlier removed in controls.
f n = 168 cases & n = 170 controls.
g n = 181 cases & n = 173 controls.
h n = 180 cases & n = 173 controls.
i BMI values imputed for n = 22 cases, sample size n = 178 cases & n = 172 controls.white cases and controls. The G allele of rs11792480
(71.7% vs. 63.0%, P = 0.01), the A allele of rs10121110
(66.0% vs. 55.3%, P = 0.004), and the G allele of
rs6550005 (84.0% vs. 77.6%, P = 0.03) were overrepre-
sented in white cases. Allelic distributions for all SNPs
in TGFβR1, ALK1, and TGFβ1, along with the remaining
SNPs in ENG and TGFβR2, were not significantly differ-
ent in the white subgroup.
The genotype for ENG tSNP rs10121110 (AA vs. GG
vs. AG) was also significantly associated with preeclamp-
sia (P = 0.02) in the white subgroup. This association
was further explored with binary logistic regression, and
odds ratios were generated. Because of multiple testing,
we evaluated logistic regression results with α = 0.01
(Table 4). Women inheriting the AA genotype for
rs10121110 were 2.29 times more likely to develop pre-
eclampsia compared to women inheriting the GG geno-
type (P = 0.008, [99% CI: 1.02 to 5.13]). The genotype for
TGFβR2 tSNP rs6550005 (GG vs. AA + GA) was also
significantly associated with preeclampsia in the white
subgroup (P = 0.04), but further exploration of this asso-
ciation with logistic regression and a more stringent cri-
terion for significance (P < 0.01) did not support this
association (Table 4). Genotype tests for all SNPs in
TGFβR1, ALK1, and TGFβ1, along with the remaining
SNPs in ENG and TGFβR2, demonstrated no significant
differences in whites.
In the black subgroup, allelic frequency distributions
for one tSNP in TGFβR1 (rs10739778: A/C alleles) and
three tSNPs in TGFβR2 (rs6550005: G/A alleles;
rs1346907: C/T alleles; rs877572: G/C alleles) weretics
) Controls (n = 174) p-value
28.4 (5.7) 0.87a
1 (1-8) 0.08b
139 (79.9%) 0.85c
39.6 (1.1) < 0 .001d
3481.6 (446.3) < 0.001d
112.1 (7.5) < 0.001d
68.1 (4.9) < 0.001d
120.4 (10.2) < 0.001d
72.3 (7.2) < 0. 001a
22.9 (16-37) < 0.001b
um-maximum); wks, weeks; Avg. SBP, average systolic blood pressure; mmHg,
index.
Table 3 Black subgroup demographic and clinical characteristics
Variable Cases (n = 30) Controls (n = 30) p-value
Maternal age, years (Mdn (min-max)) 20.0 (14-37) 20.0 (14-37) 0.99a
Gravida (Mdn (min-max)) 1 (1-6) 1 (1-6) 0.38a
Nulliparous (n, %) 25 (83.3%) 25 (83.3%) —————
Gestational age at delivery, wks (Mdn (min-max)) 36.9 (27.4-40.0) 40.6 (37.1-42.1) < 0.001a
Birthweight, grams (M (SD)) 2313.9 (715.8) 3388.8 (405.3) < 0.001b
Avg. SBP < 20 weeks’, mm Hg (M (SD))c 113.3 (9.2) 114.4 (6.8) 0.60d
Avg. DBP < 20 weeks’, mm Hg (M (SD)) c 70.4 (6.5) 69.2 (4.2) 0.41d
Avg. SBP in labor, mm Hg (M (SD))e 159.9 (17.8) 120.7 (9.1) < 0.001b
Avg. DBP in labor, mm Hg (M (SD))e 97.1 (10.4) 72.6 (7.4) < 0.001d
Pre-pregnancy BMI (Mdn (min-max))f 23.0 (17.7-38.4) 25.8 (19.4-49.9) 0.25a
Abbreviations: (Mdn (min-max)), median (minimum-maximum); wks, weeks; (M (SD)), mean (standard deviation); Avg. SBP, average systolic blood pressure; mmHg,
millimeters of mercury; Avg. DBP, average diastolic blood pressure; BMI, body mass index.
a Mann–Whitney U test.
b Independent samples t-test with unequal variances.
c n = 24 cases & n = 29 controls.
d Independent samples t-test.
e n = 30 cases & n = 29 controls.
f n = 27 cases & n = 30 controls.
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of rs10739778 (79.3% vs. 56.7%, P = 0.008), the A allele
of rs6550005 (46.7% vs. 26.7%, P = 0.02), the C allele of
rs1346907 (70.0% vs. 63.3%, P = 0.04), and the G allele of
rs877572 (70.0% vs. 61.7%, P = .03) were overrepresented
in black cases. Allelic distributions for all SNPs in ALK1,
TGFβ1, and ENG, along with the remaining SNPs in
TGFβR1, TGFβR2, were not significantly different in the
black subgroup.Table 4 Logistic regression for tSNPs with significant
genotype tests
White Subgroup
Gene/tSNP Genotype Groups OR 99% CI p-valuea
ENG: rs10121110 AA vs. GG 2.29 1.02 - 5.13 0.008
AG vs. GG 1.52 0.69 - 3.36 0.17
TGFBR2: rs6550005b GG vs. AA + GA 1.60 0.89 - 2.87 0.04
Black Subgroup
Gene/tSNP Genotype Groups OR 99% CI p-value
TGFβ1: rs4803455 AA vs. CC 0.39 0.06 - 2.61 0.20
CA vs. CC 3.04 0.56 - 16.33 0.09
TGFβ1:rs4803457 TT vs. CC 3.50 0.50 - 24.53 0.10
CT vs. CC 7.44 1.19 - 46.41 0.005
TGFβR1: rs10739778 CC vs. AA 0.19 0.02 - 2.08 0.07
AC vs. AA 0.24 0.05 - 1.09 0.02
Abbreviations: tSNP, tagging single nucleotide polymorphism; OR, odds ratio;
CI, confidence interval.
a α set at 0.01 because of multiple testing.
b SNP genotypes dichotomized (homozygote wildtype, homozygote variant +
heterozygote) due to small homozygote variant frequencies in either cases,
controls, or both.The genotype for TFGβ1 tSNP rs4803455 (CC vs. AA
vs. CA) was significantly associated with preeclampsia
(P = 0.01) in the black subgroup. However, evaluation of
the association by binary logistic regression did not sup-
port this association at α = 0.01 (Table 4). TGFβ1 tSNP
rs4803457 genotype (CC vs. TT vs. CT) was also signifi-
cantly associated with preeclampsia in the black sub-
group (P = 0.01). Further analysis of rs4803457 revealed
that women inheriting the CT genotype were 7.44 times
more likely to develop preeclampsia compared to
women inheriting the CC genotype (P = 0.005, [99% CI:
1.19 to 46.41]). Lastly, the genotype for TGFβR1 tSNP
rs10739778 (AA vs. CC vs. AC) was significantly associ-
ated with preeclampsia in the black subgroup (P = 0.03).
However, further exploration with binary logistic regres-
sion did not support this association (Table 4). Genotype
tests for all SNPs in ALK1, ENG, and TGFβR2, along
with the remaining SNPs in TGFβR1, and TGFβ1, dem-
onstrated no significant differences in the black
subgroup.
ENG haplotype TACGA associated with preeclampsia in
white subgroup
We estimated linkage disequilibrium and haplotypes for
ENG in whites. Pairwise R2 values ranged from 0.007-
0.64. For rs10121110 and rs11792480, which were both
significantly associated with preeclampsia and are sepa-
rated by about 4000 bases, R2 = 0.29. These results valid-
ate our tSNP selection criteria and indicate that
haploblocks tagged by rs10121110 and rs11792480 are
independently associated with preeclampsia.
Nineteen possible haplotypes were estimated across
the ENG tSNPs (rs10987746, rs10819309, rs10760505,
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were present in whites (Additional file 1: Table S1). ENG
haplotype distributions (CGTGA, TACAG, TACGA, and
combined) were significantly different in cases and con-
trols (χ2(3) = 8.26, P = 0.04). The TACGA allele, which
contains the risk alleles from our significantly associated
tSNPS, was over-represented in cases (χ2(1) = 5.23, P =
0.02) when compared to the other alleles combined. We
also observed a 6.1% difference in TACGA frequency
among whites and blacks (19.7% vs.13.6%). Diplotype
analysis in whites found no significant differences in
ENG diplotypes among cases and controls (χ2(4) = 7.28,
P = 0.12).
Discussion
This study begins to examine the association between
ENG pathway genetic variation and preeclampsia. In our
white sample, variation in ENG and TGFβR2 appears to
be associated with preeclampsia while variation in
TGFβ1 (excluding rs8179181- not genotyped), TGFβR1,
and ALK1 was not associated with preeclampsia. In our
smaller black sample, pathway associations also
appeared, but were different. As with whites, variation in
TGFβR2 was associated with preeclampsia, but variation
in ENG was not. In blacks, but not whites, pathway vari-
ation was suggested for TGFβ1 and TGFβR1. As with
whites, variants in ALK1 were not associated with pre-
eclampsia. These results suggest that ENG pathway gen-
etic variation is associated with preeclampsia, with
different pathway genes contributing to preeclampsia de-
velopment in white and black women.
In this study we used a very strict definition of pre-
eclampsia that included both incremental and absolute
increases in blood pressure, as well as hyperuricemia.
We believe such rigor is necessary for genetic studies of
preeclampsia, but this approach limited sample sizes.
Further, because of multiple comparisons, we explored
significant genotype findings (P < 0.05) with binaryFigure 1 Endoglin gene structure. ENG extracellular domain exons (vertic
domain exon (white). tSNPs with significant allele &/or genotype tests are b
[22,24-27].logistic regression using a more stringent level of signifi-
cance (α = 0.01), which again limits our definitive find-
ings. Nonetheless, we believe that using this strategy of
examining genotypic variation in pathway analysis to
support the role of a potential pathogenic factor pro-
vides useful insights to guide further studies of specific
pathway variation.
Are the pathway associations we have demonstrated
biologically plausible? Although we do not know the
functional consequences of these associations, several
explanations could account for the association between
ENG (rs10121110 and rs11792480) and TGFβR2
(rs6550005) genetic variation and preeclampsia in white
women. Intronically located between the second and
third exons, rs10121110 tags a genomic region that in-
cludes ENG’s promoter (Figure 1). Given rs10121110’s
location, this tSNP potentially identifies a correlated pro-
moter variant that has the ability to impact transcription
factor access/binding (e.g., SP1 transcription factor,
SMAD binding elements) [24] and subsequent transcrip-
tion/translation of ENG.
Knockdown of ENG in a human extravillous tropho-
blast cell line with short hairpin RNA specific for ENG
[10] or knockdown of first trimester human trophoblast
villous explants with antisense endoglin nucleotides [9]
improves extravillous trophoblast invasive capacity,
which is essential to uterine spiral artery remodeling in
pregnancy [9,10]. In preeclampsia, placental concentra-
tions of ENG mRNA are elevated throughout pregnancy
[12,16-18] and spiral artery remodeling is shallow [11].
Therefore, a variant within ENG’s promoter could in-
crease expression of placental ENG, which could inhibit
extravillous trophoblast invasion of the spiral arteries,
leading to shallow implantation and reduced placental
perfusion. In a setting with increased concentration of
membrane-bound ENG receptors, mass action predicts
that more will be cleaved by MMP-14, resulting in in-
creased sENG, which is found in women withal lines), transmembrane domain exon (black), and the intracellular
olded. The following resources were utilized to create the figure
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lial dysfunction [18]. Studies examining ENG’s promoter,
its transcription factors, and MMP-14 are needed to bet-
ter understand mechanisms that drive observed differ-
ences in ENG and sENG.
ENG tSNP rs10121110 is also located between exons
coding for ENG’s extracellular domain, as is rs11792480,
the other tSNP associated with preeclampsia in whites
(Figure 1). As part of TGFβ1’s signaling cascade,
TGFβR1 interacts with amino acid residues 26-437 of
ENG’s extracellular domain [25]. Only through inter-
action of ENG and type 1/2 receptors can ENG gain ac-
cess to TGFβ1 [25]. Genetic variation within exons that
code for the extracellular domain could therefore influ-
ence ENG’s ability to interact with TGFβR1, affecting
ENG’s access to TGFβ1 and the transmission of TGFβ1
signals. Because TGFβ1 induces ENG expression [10]
and stimulates ENG promoter activity [28], genetic vari-
ation that affects the degree of TGFβ1 transmission may
also explain differences in ENG expression (mRNA) be-
tween women with/without preeclampsia. Studies exam-
ining genetic regions tagged by rs10121110 and
rs11792480 may provide insight into ENG’s involvement
in preeclampsia.
TGFβR2 tSNP rs6550005, which was associated with
preeclampsia in both groups, is intronically located be-
tween the first two exons that lie adjacent to the
TGFβR2 promoter. As a result, rs6550005 may tag a
promoter variant that influences TGFβR2 transcription
and translation. Because ENG only binds TGFβ1 ligand
in the presence of type 1/2 signaling receptors [25], al-
teration in TGFβR2 transcription/translation could im-
pact the number of TGFβR2 receptors available for ENG
interaction and transmission of TGFβ1 ligand signaling.
Furthermore, this association in whites and blacks po-
tentially indicates that there is also one component of
the ENG pathway that similarly contributes to PE devel-
opment regardless of ancestry, but because the minor al-
lele frequencies differed in whites and blacks (0.192 vs.
0.367), we did not combine the data from these two
groups.
Our exploratory examination in black women revealed
that different genes from different components of the
ENG pathway (TGFβ1 and TGFβR1, but not ENG) were
associated with preeclampsia compared to white women.
These results suggest that the pathway’s involvement in
preeclampsia may differ in blacks and whites. Interest-
ingly, in a study comparing TGFβ1 mRNA and protein
levels in nonpregnant black and white hypertensive sub-
jects, TGFβ1 protein levels were significantly higher in
blacks compared to whites (P < 0.001) [29].
One additional study has investigated the association
between ENG and preeclampsia in white and black
women using a pre-designed IBCv2 array (Illumina Inc,San Diego, CA) [30]. Unlike the significant associations
found between ENG and preeclampsia in our white sub-
group, their study failed to find significant associations
in a much smaller white subgroup that was likely under-
powered. Consistency in our findings from allele, geno-
type, and haplotype tests of ENG increases our
confidence in our findings. In both studies, associations
between ENG and preeclampsia were non-significant in
blacks.
In addition to sample size, there are other limitations
to our study. Multiallelic tSNPs rs8179181 (TGFβ1) and
rs3087465 (TGFβR2) could not be genotyped despite
multiple attempts with iPLEXW and TaqManW, which
limits our ability to fully evaluate TGFβ1 and TGFβR2
genetic variability. Our black subgroup was likely under-
powered. This was not an issue in the white sample,
which generated a power ranging from 0.898 to 0.999
(Additional file 1). Additionally, we selected tSNPs for
CEU ancestry, which may have resulted in decreased in-
formativeness in blacks since haploblocks tagged by
tSNPs selected for CEU ancestry may differ from
haploblocks tagged by tSNPs selected for African ances-
try. Finally, we used self-reported race to match controls
to cases on ancestry. Because this may not reliably ac-
count for population admixture, the use of ancestral in-
formative markers in future studies represents a more
robust approach that statistically accounts for population
admixture.Conclusions
In summary, our study demonstrated that ENG pathway
genetic variation is associated with preeclampsia in
white and black women. Our results further suggest that
the pathway’s involvement in preeclampsia differs in
whites and blacks, with ENG and TGFBR2 being associ-
ated in whites and TGFβ1, TGFβR1, and TGFβR2 being
associated in blacks. Validation of results is needed to
confirm these preliminary findings. Moreover, the ENG
pathway tSNPs found to be significantly associated with
preeclampsia likely represent surrogate markers, which
tag genomic regions that contain causal variants. Fo-
cused examination of genomic regions (e.g., ENG pro-
moter sequencing) tagged by these SNPs will further
improve understanding of the ENG pathway’s role in
preeclampsia.Additional file
Additional file 1: Variation in endoglin pathway genes is associated
with preeclampsia: A case-control candidate gene association study.Competing interests
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